In a single month, three reports describe different views of China's economic future
The director known for adding depth to the mundane will make the case that Gap's "Dress Normal" doesn't equal "dress boring"
Three times more money has been spent on the race for the state's school's chief than on the governor's race
An IT expert offers an estimate of what a 50-employee small business might spend to protect against cyberattacks
A slowdown in funding could end the growth of U.S. oil production
Independent developer Lucas Menge took it upon himself to adapt the smartwatch's home screen for the iPhone
Starbucks will start a coffee delivery program in late 2015, giving other companies' employees one fewer excuse to leave the office
New government rules could block 500 colleges from federal aid money and put hundreds more in danger of losing it
Candy sales are increasing, but big drugstores and supermarkets benefit more than local candy shops
Founder: Dr. John Hadden
VC Investment over the last four quarters: $25 million
IRX Therapeutics is a 40-employee biotech firm developing drugs to restore immune system function, particularly in patients with head and neck cancer. Founded over a decade ago and backed by more than $60 million raised mostly from high-net-worth individuals, the company has reduced headcount by a third and delayed some clinical trials planned for 2009, according to Chief Financial Officer Jeffrey Hwang.
Key to startup success: "In normal times where the capital is available, the difference maker among people with good ideas is sharp execution. There's never a substitute for the ability to attract and retain experienced, qualified people to take advantage of the discovery you've made."